Sabine Schroeder

Mrs. Sabine Schroeder

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
PMPilar Guatibonza Moreno
Pilar Guatibonza Moreno
LPLuba M. Pardo
Luba M. Pardo
CPCatarina Pereira
Catarina Pereira
SSSabine Schroeder
Sabine Schroeder
DVDeepthi Vagiri
Deepthi Vagiri
ABAida Maria Bertoli-Avella
Aida Maria Bertoli-Avella
Niemann-Pick type C1 disease (NPC1 [OMIM 257220]) is a rare and severe autosomal recessive disorder, characterized by a multitude of neurovisceral clinical manifestations and a fatal outcome with no effective treatment to date. Aiming to gain insights into the genetic aspects of the disease, clinical, genetic, and biomarker PPCS data from 602 patients referred from 47 countries and diagnosed with NPC1 in our laboratory were analyzed. Patients’ clinical data were dissected using Human Phenotype Ontology (HPO) terms, and genotype–phenotype analysis was performed. The median age at diagnosis was 10.6 years (range 0–64.5 years), with 287 unique pathogenic/likely pathogenic (P/LP) variants identified, expanding NPC1 allelic heterogeneity. Importantly, 73 P/LP variants were previously unpublished. The most frequent variants detected were: c.3019C > G, p.(P1007A), c.3104C > T, p.(A1035V), and c.2861C > T, p.(S954L). Loss of function (LoF) variants were significantly associated with earlier age at diagnosis, highly increased biomarker levels, and a visceral phenotype (abnormal abdomen and liver morphology). On the other hand, the variants p.(P1007A) and p.(S954L) were significantly associated with later age at diagnosis (p < 0.001) and mildly elevated biomarker levels (p ≤ 0.002), consistent with the juvenile/adult form of NPC1. In addition, p.(I1061T), p.(S954L), and p.(A1035V) were associated with abnormality of eye movements (vertical supranuclear gaze palsy, p ≤ 0.05). We describe the largest and most heterogenous cohort of NPC1 patients published to date. Our results suggest that besides its utility in variant classification, the biomarker PPCS might serve to indicate disease severity/progression. In addition, we establish new genotype–phenotype relationships for “frequent” NPC1 variants.

1 January 1998 in Endocrine Research
Verified
Journal Article
Closed access
PDF file
GWGernot W. Wolkersdörfer
Gernot W. Wolkersdörfer
CMChristian Marx
Christian Marx
TLTobias Lohmann
Tobias Lohmann
SBSilke Brauer
Silke Brauer
SSSabine Schroeder
Sabine Schroeder
SBStefan R. Bornstein
Stefan R. Bornstein
Immunologic escape includes the loss of Fas-receptor and the gain of Fas-ligand expression. Normal adrenal glands express the Fas-receptor and MHC class II molecules in inner cortical zones. A distinctive feature of adrenocortical tumors is the loss of MHC class II expression. Here we demonstrate loss of Fas and gain of Fas-ligand expression in the adrenocortical carcinoma cell line NCI-H295 by immunohistochemistry and RT-PCR. In a co-culture system of turnor cells and HLA-matched leukocytes, CD 8-positive or CD 4-positive lymphocytes, we examined the immunologic escape and the ability to induce apoptosis in the immune cells. The direct co-culture with either leukocytes, CD 8-positive or CD 4-positive lymphocytes reduced spontaneous apoptosis in immunecells from 49.9% to 13.0%, 8.6% and 15.3%, respectively, as determined by FACS analysis of Annexin V binding and LDH release in the medium. In co-culture, cortisol secretion increased up to 200%. Cellular communication does not induce apoptosis in immune cells, but promotes their survival. This may be due to partial HLA class I mismatches contributing to immunologic activity. The viability of the tumor cells was not affected, and these cells were stimulated to secrete cortisol. In summary, immune escape of adrenocortical carcinomas may occur because of altered Fas/Fas-L system expression and loss of MHC class H expression.

28 March 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
AČAgnė Čerkauskaitė
Agnė Čerkauskaitė
JSJudy Savige
Judy Savige
KJKarolina Janonyte
Karolina Janonyte
IJIeva Jeremiciute
Ieva Jeremiciute
MMMarius Miglinas
Marius Miglinas
RCRimante Cerkauskiene
Rimante Cerkauskiene
Introduction: Alport syndrome (AS) is an inherited disorder characterized by hematuria, proteinuria, and kidney function impairment, and frequently associated with extrarenal manifestations. Pathogenic variants in COL4A5 usually cause X-linked Alport syndrome (XLAS), whereas those in the COL4A3 or COL4A4 genes are associated with autosomal dominant (AD) or recessive (AR) inheritance. To date, more than 3000 different disease-causing variants in COL4A5, COL4A3, and COL4A4 have been identified. The aim of this study was to evaluate the clinical and genetic spectrum of individuals with novel, pathogenic or likely pathogenic variants in the COL4A3-A5 genes in a previously unstudied cohort.Methods: In this study molecular analysis by next generation sequencing (NGS) was performed on individuals from a Lithuanian cohort, with suspected AS. The presence of AS was assessed by reviewing clinical evidence of hematuria, proteinuria, chronic kidney disease (CKD), kidney failure (KF), a family history of AS or persistent hematuria, and specific histological lesions in the kidney biopsy such as thinning or lamellation of the glomerular basement membrane (GBM). Clinical, genetic, laboratory, and pathology data were reviewed. The novelty of the COL4A3-A5 variants was confirmed in the genetic variant databases (Centogene, Franklin, ClinVar, Varsome, InterVar). Only undescribed variants were included in this study.Results: Molecular testing of 171 suspected individuals led to the detection of 99 individuals with 44 disease causing variants including 27, previously undescribed changes, with the frequency of 9/27 (33,3%) in genes COL4A5, COL4A3 and COL4A4 equally. Three individuals were determined as having digenic AS causing variants: one in COL4A3 and COL4A4, two in COL4A4 and COL4A5. The most prevalent alterations in genes COL4A3-5 were missense variants (n = 19), while splice site, frameshift, unknown variant and stop codon changes were detected more in genes COL4A4 and COL4A5 and accounted for 3, 3, 1 and 1 of all novel variants, respectively.Conclusion: Genotype-phenotype correlation analysis suggested that some variants demonstrated intra-familial phenotypic variability. These novel variants represented more than half of all the variants found in a cohort of 171 individuals from 109 unrelated families who underwent testing. Our study expands the knowledge of the genetic and phenotypic spectrum for AS.

15 May 2024 in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
Verified
Journal Article
Open access
PDF file
EJEresha Jasinge
Eresha Jasinge
MFMihika Fernando
Mihika Fernando
NINeluwa-Liyanage Ruwan Indika
Neluwa-Liyanage Ruwan Indika
PRPyara Dilani Ratnayake
Pyara Dilani Ratnayake
NGNalin Gamaathige
Nalin Gamaathige
ARArndt Rolfs
Arndt Rolfs
Resumen: Objetivos: La piruvato carboxilasa (PC), una enzima mitocondrial, cataliza la conversión de piruvato, producto final de la glucólisis, en oxaloacetato, un intermediario del ciclo del ácido tricarboxílico. El déficit de piruvato carboxilasa, un trastorno raro, se manifiesta en tres fenotipos clínicos y bioquímicos: tipo de inicio neonatal (tipo A), tipo de inicio infantil (tipo B) y un tipo benigno (tipo C). Caso clínico: Presentamos el caso de tres neonatos de Sri Lanka, incluidos dos hermanos, de dos familias no emparentadas, con déficit de piruvato carboxilasa (DPC). Los tres desarrollaron dificultad respiratoria en las primeras horas de vida. Los dos hermanos presentaron las alteraciones bioquímicas típicas del tipo B. El tercer neonato presentaba niveles normales de citrulina y lisina, niveles moderados de lactato, lesiones quísticas paraventriculares, deformidades óseas y una nueva variante homocigótica sin sentido c.2746G>C [p.(Asp916His)] en el gen PC, indicativos bioquímicos de DPC tipo A. Conclusiones: Nuestros hallazgos indican la urgencia de realizar estudios analíticos en los neonatos que presenten taquipnea con acidosis metabólica concomitante, dado que la identificación temprana es crucial para el manejo del paciente y la prestación de consejo genético a la familia. Son necesarios más estudios para identificar los síntomas y alteraciones bioquímicas concurrentes en los diferentes fenotipos de déficit de piruvato carboxilasa.

17 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SRSabine Rösner
Sabine Rösner
LPLuba Pardo
Luba Pardo
ABAida Maria Bertoli-Avella
Aida Maria Bertoli-Avella
VSVolha Skrahina
Volha Skrahina
PEPierre Engel
Pierre Engel
PBPeter Bauer
Peter Bauer
Background: Hereditary transthyretin-related amyloidosis is a clinically heterogeneous autosomal dominant disease caused by pathogenic variants in the TTR gene (hATTR amyloidosis). Objective: The current study describes the demographic, clinical, and genetic characteristics of patients with suspected hATTR amyloidosis. Methods: This study is part of the “Hereditary transthyretin-related amyloidosis and longitudinal monitoring of TTR-positive patients” (TRAMmoniTTR) study. This study included 3167 participants, along with their clinical details. Principal component (PC) analysis was used to analyze their clinical symptomatology. Next-generation sequencing of the TTR gene was performed and genotype–phenotype relationships were investigated. We compared the demographic and clinical characteristics using the principal components (PCs) and also compared participants with and without the TTR pathogenic variants. Results: We identified five main clinical phenotypes out of 22 single symptoms that explained 49% of the variation. The first two PCs referred to polyneuropathy and cardiomyopathy. We found significant differences between gender and PC-polyneuropathy and PC-cardiomyopathy, with male over-representation in the higher quantiles of PC-polyneuropathy and male under-representation in the lowest quantiles of PC-cardiomyopathy. We identified 92 participants with hATTR (3%), exhibiting 17 unique heterozygous TTR variants. The p.Val50Met variant was the most frequent. Furthermore, 503 participants (20%) were identified with ATTR and no relevant TTR variants (ATTRwt). We detected significant differences between the ATTRwt and hATTR groups, with male gender predominance in only the ATTRwt group and a positive family history of polyneuropathy and/or cardiomyopathy among the hATTR participants. Conclusions: The current clinical and genetic characterization of this cohort serves as a foundation for further longitudinal monitoring and assessment.

1 August 2025 in Neurology Genetics
Verified
Journal Article
Open access
TBTobias Boettcher
Tobias Boettcher
CBChristian Beetz
Christian Beetz
DSDaniel Schulze
Daniel Schulze
DSDeepa Saravanakumar
Deepa Saravanakumar
EZEmir Zonic
Emir Zonic
PBPeter Bauer
Peter Bauer
Fabry disease (FD) is a multisystemic disorder caused by pathogenic variants in the α-galactosidase (GLA) gene. There is ongoing debate on the disease-causing properties of the GLA variant NM_000169.3: c.937G > T, p.Asp313Tyr (D313Y). Like many others, we recently reclassified this variant from “variant of uncertain significance” to “benign.” By leveraging Centogene's Biodatabank, we reassessed our classification and analyzed all samples (n = 38,242) molecularly tested for FD from Germany between 2015 and 2020 for GLA genotypes, clinical presentations, and biochemical phenotypes. The allele frequency of GLA variant p.Asp313Tyr in our cohort was increased compared with gnomAD v4.1.0 data for European (non-Finnish) population resulting in an odds ratio of 2.13 (95% CI 1.94–2.33; p < 0.0001). Compared with individuals without any GLA variant, there was no specific clinical nor biochemical phenotype in this group, supporting a diagnosis of FD. GLA variant p.Asp313Tyr is to be classified as a benign variant and does not cause FD. Because an enrichment of patients with this variant in specific high-risk populations has been seen in this cohort and by other groups, properly designed case-control studies are needed to clarify a potential role of p.Asp313Tyr as risk factor or modifier of a FD-independent dysfunction.